News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opko Health, Inc. Release: Data Supporting Once-Weekly Dosing Of hGH-CTP In Growth Hormone Deficient Pediatric Population To Be Presented At The 2014 ICE/ENDO Meeting


5/20/2014 8:38:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OPKO Health, Inc. (NYSE: OPK), announced that it will present new clinical data on its long-acting human growth hormone product (hGH-CTP) at the ICE/Endo 2014, the joint meeting of The Endocrine Society and The International Congress of Endocrinology in Chicago on June 21st-24th.

OPKO Biologics (formerly PROLOR Biotech) scientists will present pharmacokinetic and pharmacodynamic data from the company's advanced phase 2 trial of hGH-CTP in growth hormone deficient pediatric subjects.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES